カナグリフロジン

化学名:カナグリフロジン

CAS番号.842133-18-0

英語名:Canagliflozin

CBNumberCB02510088

MFC24H25FO5S

MW444.52

MOL File842133-18-0.mol

别名

カナグリフロジン

1-[4-メチル-3-[[5-(4-フルオロフェニル)-2-チエニル]メチル]フェニル]-1-デオキシ-β-D-グルコピラノース

(1S)-1,5-アンヒドロ-1-[3-[[5-(4-フルオロフェニル)-2-チエニル]メチル]-4-メチルフェニル]-D-グルシトール

カナグリフロジン物理性質

融点	68 - 72°C
沸点	642.9±55.0 °C(Predicted)
比重(密度)	1.364
貯蔵温度	-20°C
溶解性	DMSOに可溶 (40 mg/ml)
外見	個体
酸解離定数(Pka)	13.34±0.70(Predicted)
色	白い
安定性：	-20°C の DMSO 溶液で最大 1 か月間保存できます。
InChIKey	XTNGUQKDFGDXSJ-XDLHWMRXNA-N
SMILES	O[C@@H]1[C@H]([C@H](O)[C@@H](CO)O[C@H]1C1C=CC(C)=C(CC2=CC=C(C3C=CC(F)=CC=3)S2)C=1)O \|&1:1,2,3,5,9,r\|
CAS データベース	842133-18-0

安全性情報

有毒物質データの

842133-18-0(Hazardous Substances Data)

危険有害性情報のコード(GHS)

カナグリフロジン化学特性,用途語,生産方法

説明
In March 2013, the US FDA approved canagliflozin (JNJ-28431754; TA-7284) for the treatment of type 2 diabetes in adults. Canagliflozin is the first US-approved sodium-glucose co-transporter (SGLT) inhibitor for the treatment of type 2 diabetes. Inhibition of renal SGLT suppresses glucose reabsorption, which permits glucose excretion into urine and reduction of hyperglycemia. Canagliflozin was discovered through structural modifications of phlorizin, a known inhibitor of renal glucose reabsorption. Early modifications of OH groups on the glucose moiety were insufficient to adequately impair hydrolysis by intestinal β-glucosidase. Introduction of the C-glucoside moiety, as in the clinical candidate dapagliflozin, afforded sufficient resistance to hydrolysis. Finally, incorporation of the thiophene moiety in canagliflozin provided improved potency for hSGLT2 (exclusive to kidney), IC₅₀=2.2 nM, while offering significant selectivity over hSGLT1 (in kidney and heart), IC₅₀=910 nM. Hyperglycemic, high-fat (HF) diet fedmice (KKstrain) that received a single 3 mg/kg oral dose of canagliflozin had a 48% reduction in blood glucose levels after 6 h versus vehicle-treatedmice. Noteworthy in themultistep synthesis of canagliflozin is the stereoselective formation of the β-C-glucoside which is accomplished by coupling of the aryllithiumaglycone with 2,3,4,6-tetra-O-trimethylsilyl-β-Dgluconolactone followed by desilylation and stereoselective reduction with triethylsilane and boron trifluoride etherate.
化学的特性
Pale Yellow Solid
使用
Canagliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Canagliflozin has been shown to dose dependently reduce calculated renal threshold for glucose excretion and increase urinary glucose excretion. Canagliflozin is a candidate for the treatment of type 2 diabetes and obesity.
定義
ChEBI: A C-glycosyl compound that is used (in its hemihydrate form) for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2.

カナグリフロジン生産企業

カナグリフロジンスペクトルデータ(¹HNMR)

842133-18-0, カナグリフロジンキーワード

Send Inquriy

カナグリフロジン

危険有害性情報のコード(GHS)

カナグリフロジン 化学特性,用途語,生産方法

カナグリフロジン 生産企業

カナグリフロジン スペクトルデータ(1HNMR)

842133-18-0, カナグリフロジン キーワード

カナグリフロジン化学特性,用途語,生産方法

カナグリフロジン生産企業

カナグリフロジンスペクトルデータ(¹HNMR)

842133-18-0, カナグリフロジンキーワード